Akums Drugs and Pharmaceuticals Limited - chemicals in Delhi, India. FY 2026 financials & compliance.
CIN L24239DL2004PLC125888 Incorporated 19 April 2004 ROC Delhi HQ Delhi, India
Active Listed - NSE: AKUMS · BSE: 544222 Public Limited Company chemicals
Market Cap
₹11,220 Cr
AKUMS · NSE
Share Price
₹696.20
-2.34% today
Revenue
₹4,359 Cr
FY 2025-26 · +5.9% YoY
EBITDA
₹502 Cr
Margin 11.5%
Net Profit
₹269 Cr
FY 2025-26 · -16.7% YoY
P/E (TTM)
29.9x
P/B 3.2x
ROE
8.1%
ROCE 12.5%
Debt / Equity
0.04
Interest cover 27.1x

About Akums Drugs and Pharmaceuticals Limited

Data last updated:

Akums Drugs and Pharmaceuticals Limited is a public limited company based in Delhi, India. It operates in the chemical products segment of the chemicals sector. It was incorporated on 19 April 2004 and has been in existence for over 22 years.

Its director Sanjeev Jain is #655 among India's richest people (2026). Its director Sandeep Jain is #655 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Delhi, under CIN L24239DL2004PLC125888. Its GSTIN is 07AAECA7090B2ZX (Delhi). The company holds 9 GST registrations, of which 5 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 544222 and NSE: AKUMS.

The company has an authorised share capital of ₹40 Cr and a paid-up capital of ₹31.48 Cr. It is led by directors including Sandeep Jain (Managing Director) and Sanjeev Jain (Managing Director).

Its last annual general meeting (AGM) was held on 10 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 304 Mohan Placelsc Saraswati Vihar, Delhi, India – 110034.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹4,359.02 Cr, a growth of 5.8% compared to the previous year. For the same year it recorded a net profit of ₹268.66 Cr (net margin 6.2%) and EBITDA of ₹502.01 Cr (EBITDA margin 11.5%). The net worth stands at ₹3,313.35 Cr (up 8.7% YoY). Total assets are valued at ₹4,415.09 Cr (up 37% YoY).

The company has about 1,707 employees on its provident fund (EPFO) records. Its group structure includes 14 subsidiaries.

The company is associated with 3 brands: Unosource Pharma, Akums and Akumentis Heathcare. As per MCA filings, the company has open charges of ₹85 Cr and satisfied charges of ₹468.39 Cr on record. Court records list 206 cases involving the company, including 138 filed by the company and 68 filed against it; 51 cases are pending. The company has 13 deals on record (9 secondary share transfers, 2 market trades, 1 ipo), with disclosed funding of ₹320 Cr; the latest was in December 2025. Its 5 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations) are compared by revenue, 2 larger and 3 smaller; the largest is Strides Pharma Science Limited with revenue of ₹4,624.06 Cr. The company has 2 MSME Form 1 returns on record between 2019 and 2021, listing 8 overdue payments to 8 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website akums.in.

Company details

CIN L24239DL2004PLC125888
Registration Number 125888
Incorporation Date 19 April 2004
ROC Delhi
Listing Status Listed - Listed on NSE (AKUMS); Listed on BSE (544222)
Company Status Active
Compliance Status Active Compliant

CIN history

Akums Drugs and Pharmaceuticals has one previous CIN (Corporate Identification Number): U24239DL2004PLC125888. The current CIN is L24239DL2004PLC125888, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24239DL2004PLC125888Current
U24239DL2004PLC125888Previous

Recognitions & Rankings of Akums Drugs and Pharmaceuticals

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#491
Valuation
₹9,840 Cr
India's Richest People 2026 edition · 2 directors · Source: Hurun India

Contact details

Akums Drugs and Pharmaceuticals Limited's registered office is in Delhi, Delhi. Its website is akums.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
  • Social Media
  • Registered Address
    304 Mohan Placelsc Saraswati Vihar, Delhi, India – 110034
  • Industry
    Chemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals

To see the full contact details of Akums Drugs and Pharmaceuticals Limited, buy the company report.

Comprehensive company report
Akums Drugs and Pharmaceuticals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Akums Drugs and Pharmaceuticals operates multiple associated brands including Unosource Pharma, Akums, and Akumentis Heathcare. Each brand links to its own profile.

BrandDescriptionWebsite
Pharmaceutical manufacturing, exporting, and CDMO services.unosourcepharma.com
CDMO focusing on spectrum of dosage forms and therapeutic segmentsakums.in
Pharmaceutical products are manufactured across multiple therapeutic areas.akumentishealthcare.com

Business activity

The main business activity of Akums Drugs and Pharmaceuticals is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Akums Drugs and Pharmaceuticals Limited, buy the company report.

Financials of Akums Drugs and Pharmaceuticals Limited

FY 2025-26 filings available

Akums Drugs and Pharmaceuticals Limited reported revenue of ₹4,359.02 Cr (up 5.8% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹4,359 Cr
+5.8% YoY
EBITDA
₹502 Cr
+8.1% YoY
Profit After Tax
₹269 Cr
-16.7% YoY
Net Worth
₹3,313 Cr
+8.7% YoY
Total Assets
₹4,415 Cr
+37.0% YoY
Total Debt
₹157 Cr
+78.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,3594,1184,1783,6553,6722,7232,414
Revenue growth+5.9%-1.4%+14.3%-0.5%+34.9%+12.8%-
EBITDA50246496.95219(105)227173
EBITDA margin+11.5%+11.3%+2.3%+6.0%-2.9%+8.4%+7.2%
Profit before tax382345(45.27)150(193)172114
Net profit269323(20.67)127(244)13044.09
Net profit margin+6.2%+7.8%-0.5%+3.5%-6.6%+4.8%+1.8%
EPS (₹)16.6722.09(0.28)6.63(35.30)943.16335.65
Balance sheet
Total assets4,4153,2222,7132,4042,1091,6471,439
Net worth3,3133,047710717622885722
Total debt15788.22565619395130175
Cash & bank1,68157627715010367.87147
Net working capital2,5461,4021,1491,042943659679
Cash flow
Cash from operations1,18146549817731.8513128.13
Cash from investing(930)(548)(331)(305)(235)(109)(190)
Cash from financing33.8872.79(108)125236(91.46)233
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,3421,1671,1581,1601,0181,0241,0561,010
Revenue growth (YoY)+31.9%+13.9%+9.7%+14.8%-1.5%+0.5%--
Other income28.9130.3835.3034.3332.3726.7325.7619.34
EBITDA19517515012994.4812993.92121
EBITDA margin+14.5%+15.0%+12.9%+11.1%+9.3%+12.6%+8.9%+12.0%
Depreciation43.2141.0740.1239.6537.8636.9240.0044.52
Interest25.6824.7623.8923.7423.3023.144.545.13
Profit before tax15513912199.5765.6995.6475.1491.05
Tax40.1838.2639.8731.8922.9830.96(74.47)24.75
Net profit11510181.3567.6842.7164.6815066.30
EPS (₹)7.376.535.534.332.664.159.644.26
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,3491,3121,4441,2871,162837737
Revenue growth+2.8%-9.2%+12.2%+10.7%+38.8%+13.6%-
EBITDA90.96138(146)97.34(362)(223)39.93
EBITDA margin+6.7%+10.6%-10.1%+7.6%-31.2%-26.6%+5.4%
Profit before tax148208(103)150(335)(195)75.85
Net profit117158(157)231(383)11050.84
Net profit margin+8.6%+12.1%-10.9%+17.9%-32.9%+13.2%+6.9%
EPS (₹)7.2910.52(11.56)8.77(53.37)(1,117.82)391.04
Balance sheet
Total assets2,5162,3741,7961,5211,3891,1761,262
Net worth2,4282,305144312186567712
Total debt59.2146.2926714614041.1335.80
Cash & bank77135673.318.8525.741.0072.48
Net working capital1,035530244148143230352
Cash flow
Cash from operations(2.15)91.0024894.0122855.57(21.75)
Cash from investing(24.97)(459)(165)(202)(298)(99.96)(242)
Cash from financing(3.00)375(20.74)89.9094.992.60302
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue395392338369309332329337
Revenue growth (YoY)+27.7%+18.0%+2.9%+9.3%-5.8%+4.8%--
Other income25.8026.1027.7329.6027.0828.5632.0533.84
Total expenses360344329348292288311303
EBITDA34.5748.519.0720.8716.9044.1017.7234.03
EBITDA margin+8.8%+12.4%+2.7%+5.7%+5.5%+13.3%+5.4%+10.1%
Depreciation13.5112.8012.4212.1510.6910.2510.0910.68
Interest3.002.482.592.462.082.912.632.29
Profit before tax43.8659.3321.7935.8631.2159.5037.0554.90
Tax11.2114.506.607.757.7414.649.4713.73

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 20 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,3421,1671,1581,1601,0181,0241,0561,010
Revenue growth (YoY)+31.9%+13.9%+9.7%+14.8%-1.5%+0.5%--
Other income28.9130.3835.3034.3332.3726.7325.7619.34
EBITDA19517515012994.4812993.92121
EBITDA margin+14.5%+15.0%+12.9%+11.1%+9.3%+12.6%+8.9%+12.0%
Depreciation43.2141.0740.1239.6537.8636.9240.0044.52
Interest25.6824.7623.8923.7423.3023.144.545.13
Profit before tax15513912199.5765.6995.6475.1491.05
Tax40.1838.2639.8731.8922.9830.96(74.47)24.75
Net profit11510181.3567.6842.7164.6815066.30
EPS (₹)7.376.535.534.332.664.159.644.26
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,3594,1184,1783,6553,6722,7232,414
Revenue growth+5.9%-1.4%+14.3%-0.5%+34.9%+12.8%-
Other income12968.8234.0390.0722.8321.5027.49
Total expenses3,8573,6544,0813,4363,7772,4952,241
Employee cost754716647590508425439
EBITDA50246496.95219(105)227173
EBITDA margin+11.5%+11.3%+2.3%+6.0%-2.9%+8.4%+7.2%
Depreciation15515312611394.6869.8466.68
Interest94.0734.6050.6146.2516.666.7419.93
Profit before tax382345(45.27)150(193)172114
Tax1261.48(46.07)52.4857.6848.8370.17
Net profit269323(20.67)127(244)13044.09
Net profit margin+6.2%+7.8%-0.5%+3.5%-6.6%+4.8%+1.8%
EPS (₹)16.6722.09(0.28)6.63(35.30)943.16335.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital30.6230.6228.6128.6114.311.301.30
Reserves & surplus3,2833,016681689608884721
Shareholders' funds (net worth)3,3133,047710717622885722
Minority interest17.7716.6010.996.193.202.29(1.51)
Secured loans72.9513.6639153735895.90140
Unsecured loans84.4874.5617482.1237.0334.0735.02
Total debt15788.22565619395130175
Total liabilities4,4153,2222,7132,4042,1091,6471,439
Assets
Gross block2,4102,2421,8821,6831,5181,321993
Net block1,4561,3971,1911,0971,021904645
Capital work in progress17716319510331.0717.0156.60
Investments0.140.140.140.140.3919.545.84
Inventories756681630730722430398
Sundry debtors797770834845884531582
Cash & bank balances1,68157627715010367.87147
Loans & advances327247200154154109117
Total current assets3,5602,2751,9411,8791,8641,1381,244
Total current liabilities1,014873792837921479565
Net working capital2,5461,4021,1491,042943659679
Total assets4,4153,2222,7132,4042,1091,6471,439
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10111151.6155.1422.0791.7920.51
Net cash from operating activities1,18146549817731.8513128.13
Net cash from investing activities(930)(548)(331)(305)(235)(109)(190)
Net cash from financing activities33.8872.79(108)125236(91.46)233
Net change in cash285(9.86)59.44(3.53)33.07(69.72)71.28
Closing cash1,68157627715010367.87147
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.9%-1.4%+14.3%-0.5%+34.9%+12.8%-
EBITDA growth+8.1%+379.1%-55.8%+309.4%-146.1%+31.4%-
PBT growth+10.7%+9998.0%-+9998.0%-+51.3%+7.7%
Net income growth-16.7%+1660.6%-116.2%+152.3%-287.8%+194.2%-
Revenue CAGR (3Y)+6.1%+3.9%+15.4%+14.8%+30.5%+23.0%-
EBITDA CAGR (3Y)+31.8%--24.7%+8.2%-+22.4%-
Profitability & leverage
Net income margin+5.9%+8.4%+0.0%+2.7%-6.8%+4.5%+1.8%
Return on capital employed+12.5%+12.9%+1.2%+11.7%-9.4%+11.6%+9.3%
Return on net worth+8.1%+18.3%-2.2%+19.5%-33.3%+15.4%+6.0%
Debt / equity0.040.170.830.760.330.190.24
Long-term debt / equity0.020.060.240.180.030.020.01
Interest cover27.0711.12-176.4043.44-8.364.2818.75
Efficiency & per share
Fixed asset turnover1.872.002.342.282.662.352.43
Inventory turnover6.076.286.145.036.376.576.06
Debtors turnover5.565.134.984.235.194.894.15
EPS (₹)16.6722.09(0.28)6.63(35.30)943.16335.65
Dividend per share (₹)3.000.000.000.000.000.000.00
Book value per share (₹)216.41199.0149.5950.1386.956,801.285,554.41
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue395392338369309332329337
Revenue growth (YoY)+27.7%+18.0%+2.9%+9.3%-5.8%+4.8%--
Other income25.8026.1027.7329.6027.0828.5632.0533.84
Total expenses360344329348292288311303
EBITDA34.5748.519.0720.8716.9044.1017.7234.03
EBITDA margin+8.8%+12.4%+2.7%+5.7%+5.5%+13.3%+5.4%+10.1%
Depreciation13.5112.8012.4212.1510.6910.2510.0910.68
Interest3.002.482.592.462.082.912.632.29
Profit before tax43.8659.3321.7935.8631.2159.5037.0554.90
Tax11.2114.506.607.757.7414.649.4713.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,3491,3121,4441,2871,162837737
Revenue growth+2.8%-9.2%+12.2%+10.7%+38.8%+13.6%-
Other income11312494.1296.1558.4854.5165.52
Total expenses1,2581,1731,5901,1891,5241,060697
Employee cost218202175147136123124
EBITDA90.96138(146)97.34(362)(223)39.93
EBITDA margin+6.7%+10.6%-10.1%+7.6%-31.2%-26.6%+5.4%
Depreciation45.5039.5532.6930.0027.7626.1025.26
Interest10.0415.3118.3113.183.650.824.34
Profit before tax148208(103)150(335)(195)75.85
Tax36.7246.8362.5224.8946.80(49.77)24.99
Net profit117158(157)231(383)11050.84
Net profit margin+8.6%+12.1%-10.9%+17.9%-32.9%+13.2%+6.9%
EPS (₹)7.2910.52(11.56)8.77(53.37)(1,117.82)391.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital30.6230.6228.6128.6114.311.301.30
Reserves & surplus2,3972,275115283171566711
Shareholders' funds (net worth)2,4282,305144312186567712
Secured loans13.553.9322614612222.7135.80
Unsecured loans45.6642.3640.780.0018.0718.420.00
Total debt59.2146.2926714614041.1335.80
Total liabilities2,5162,3741,7961,5211,3891,1761,262
Assets
Gross block792683613532497463436
Net block425356317272253244242
Capital work in progress52.2356.748.6516.250.521.261.13
Investments36636613913914114965.35
Inventories23020216219717995.91123
Sundry debtors218206234256304212178
Cash & bank balances77135673.318.8525.741.0072.48
Loans & advances10569.2464.4358.9946.1943.02121
Total current assets1,324833533521555352494
Total current liabilities289303289373412122142
Net working capital1,035530244148143230352
Total assets2,5162,3741,7961,5211,3891,1761,262
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash76.4968.967.2325.490.1541.933.87
Net cash from operating activities(2.15)91.0024894.0122855.57(21.75)
Net cash from investing activities(24.97)(459)(165)(202)(298)(99.96)(242)
Net cash from financing activities(3.00)375(20.74)89.9094.992.60302
Net change in cash(30.11)7.5461.72(18.26)25.34(41.79)38.07
Closing cash77135673.318.8525.741.0072.48
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.8%-9.2%+12.2%+10.7%+38.8%+13.6%-
EBITDA growth-34.3%+194.8%-250.0%+126.9%-62.5%-658.0%-
PBT growth-28.6%+9998.0%-+9998.0%-71.6%--32.3%
Net income growth-26.4%+200.6%-168.3%+160.2%-447.0%+117.0%-
Revenue CAGR (3Y)+1.6%+4.1%+19.9%+20.4%+19.4%+12.0%-
EBITDA CAGR (3Y)-2.2%--13.1%+34.6%---
Profitability & leverage
Net income margin+8.3%+12.3%-11.5%+9.8%-32.9%-17.4%+6.9%
Return on capital employed+6.5%+10.7%-3.9%+21.2%-25.8%+4.5%+7.4%
Return on net worth+4.7%+13.2%-69.2%+92.8%-101.5%+17.3%+6.6%
Debt / equity0.020.130.910.570.220.050.06
Long-term debt / equity0.020.040.170.08-30,181.49-17,754.290.00
Interest cover22.0915.47-10.2419.57-0.94-0.3329.58
Efficiency & per share
Fixed asset turnover1.832.022.522.502.421.861.79
Inventory turnover6.257.228.056.848.447.656.43
Debtors turnover6.375.965.904.604.514.304.38
EPS (₹)7.2910.52(11.56)8.77(53.37)(1,117.82)391.04
Dividend per share (₹)3.000.000.000.000.000.000.00
Book value per share (₹)158.56150.5710.0621.7725.944,358.555,476.91

To see the full year-wise statements and ratios of Akums Drugs and Pharmaceuticals Limited, buy the company report.

Board of directors of Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals has 8 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Kewal Kundanlal HandaDirector16 Mar 20224 Years 8 MonthsCurrent
Matangi GowrishankarDirector16 Mar 20224 Years 8 MonthsCurrent
Sandeep JainManaging Director19 Apr 200422 Years 7 MonthsCurrent
Sanjeev JainManaging Director19 Apr 200422 Years 7 MonthsCurrent
Anilkumar Arvindlal AminDirector04 Jun 20251 Years 5 MonthsCurrent
Satwinder SinghDirector17 Jan 20242 Years 10 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Akums Drugs and Pharmaceuticals Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Strides Pharma Science Limited₹4,624.06 Cr (FY 2025)18.0%Thane, Maharashtra, India
Apl Healthcare Limited₹4,412.92 Cr (FY 2025)39.0%Hyderabad, Telangana, India
Akums Drugs and Pharmaceuticals Limitedthis company₹4,359.02 Cr (FY 2026)₹268.66 Cr6.2%5.8%1,707Delhi, India
J B Chemicals and Pharmaceuticals Limited₹3,956.31 Cr (FY 2025)12.0%Ahmedabad, Gujarat, India
Glaxosmithkline Pharmaceuticals Limited₹3,895.14 Cr (FY 2025)9.0%Mumbai, Maharashtra, India
Cadila Pharmaceuticals Limited₹3,869.17 Cr (FY 2025)4.0%Ahmedabad, Gujarat, India

To see the full peer comparison of Akums Drugs and Pharmaceuticals Limited, buy the company report.

Auditor

Akums Drugs and Pharmaceuticals Limited is audited by M/S Walker Chandiok & Llp for the financial year 2025.

Auditor firmFinancial yearFirm registration number
M/S Walker Chandiok & LlpFY 2025001076N/N500013

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 75.30%, foreign institutional investors hold 1.90%, domestic institutional investors hold 13.50% and retail and other public shareholders hold 9.30%.

Promoters: 75.30%DII (Domestic Institutional): 13.50%FII (Foreign Institutional): 1.90%Retail & Others: 9.30%
Sep 2026
QUARTER
75.30% Promoters
13.50% DII (Domestic Institutional)
1.90% FII (Foreign Institutional)
9.30% Retail & Others
Promoter holding - history
Now 75.30% · Sep 2026High 75.30% · Dec 2025Low 75.30% · Dec 2025
74%74.8%75.5%76.3%77%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 75.30%Mar 2026: 75.30%Jun 2026: 75.30%Sep 2026: 75.30%75.30%75.30%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters75.30%75.30%75.30%75.30%
Public24.70%24.70%24.70%24.70%

Charges & borrowings

Open charges
₹85 Cr
Satisfied charges
₹468.39 Cr
Breakdown by lending institutions
Sbicap Trustee Company Limited₹85.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
08 Feb 2023100679965Sbicap Trustee Company Limited₹85 CrOpen
15 Jul 2022100598017Yes Bank Limited₹60 CrSatisfied
13 Jul 2022100601001The Hongkong and Shanghai Banking Corporation Limited₹50 CrSatisfied
11 Apr 2022100565416Citi Bank N.A.₹25 CrSatisfied
16 Aug 2021100494543Hdfc Bank Limited₹60 CrSatisfied

To see the full charge records of Akums Drugs and Pharmaceuticals Limited, buy the company report.

Total charge records: 18 View all charges

Deals & funding

Akums Drugs and Pharmaceuticals Limited has 13 deals on record (9 secondary share transfers, 2 market trades, 1 ipo), with disclosed funding of ₹320 Cr; the latest was in December 2025.

Total deals
13
Secondary share transfers
9
Market trades
2
IPO
1
Funding round
1
Disclosed funding
₹320 Cr

Deals on record (5 of 13)

WhenDealAmountParties
Dec 2025Market trade₹311.52 CrBuyer: Icici Prudential Mutual Fund
Seller: Ruby Qc Investment Holdings Pte.Ltd.
Aug 2024IPO₹1,856.74 CrInvestors: IPO Shareholders - Akums Drugs And Pharmaceuticals Limited, SBI Healthcare Opportunities Fund, International Growth and Income Fund
Seller: Quadria Capital, 3 individuals
Jan 2009Secondary share transferUndisclosedBuyer: 2 individuals
Seller: Akum Pharmaceuticals Private Limited
Nov 2007Secondary share transferUndisclosedBuyer: 2 individuals
Seller: A.K. Laboratories Limited
Aug 2006Secondary share transferUndisclosedBuyer: Akum Pharmaceuticals Private Limited , 3 individuals
Seller: 4 individuals

To see the full deal history of Akums Drugs and Pharmaceuticals Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Akums Drugs and Pharmaceuticals Limited was last rated by Icra on 09 Jun 2021.

Rating agencyRated onRating
Icra09 Jun 2021

To see the full credit ratings and regulatory alerts of Akums Drugs and Pharmaceuticals Limited, buy the company report.

MSME payment delays

Akums Drugs and Pharmaceuticals Limited has 2 MSME Form 1 returns on record between 2019 and 2021, listing 8 overdue payments to 8 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 8)

SupplierAmount dueDue sinceReported on
Trident Services Private Limited
an individual supplier
Super Lifecare Private Limited
Gogia Chemical Industries Private Limited
Kumaon Exports Private Limited

To see the full MSME payment records of Akums Drugs and Pharmaceuticals Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Akums Drugs and Pharmaceuticals has 14 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

14
Subsidiary companies
Key subsidiaries
Company NameCINShares held
May and Baker Pharmaceuticals LimitedU15400DL2006PLC145272
Pure and Cure Healthcare Private LimitedU24232DL2005PTC266385
Plenteous Pharmaceuticals LimitedU24232DL2008PLC185686
Nicholas Healthcare LimitedU24232DL2009PLC186841
Unosource Pharma LimitedU24233DL2013PLC262364
Burroughs Welcome Pharmacia Private LimitedU24290DL2021PTC376044

To see the full group structure of Akums Drugs and Pharmaceuticals Limited, buy the company report.

Employees & EPFO

Akums Drugs and Pharmaceuticals Limited has a workforce of 1,707 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
1,707
Active EPFO establishments
1
Employee growth
10.1%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-271,707
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17

To see the full employee and EPFO history of Akums Drugs and Pharmaceuticals Limited, buy the company report.

GST

Akums Drugs and Pharmaceuticals has 9 GST registrations: 5 active and 4 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
9
Active
5
Cancelled / inactive
4
GSTINStateStatusRegistered on
07AAECA7090B2ZXDelhiActive26 Jul 2017
07AAECA7090B4ZVDelhiActive01 Mar 2025
05AAECA7090B1Z2UttarakhandActive01 Jul 2017
27AAECA7090B1ZWMaharashtraActive01 Aug 2019

To see the full GST registrations and return filing status of Akums Drugs and Pharmaceuticals Limited, buy the company report.

Recent activity

Akums Drugs and Pharmaceuticals Limited has 44 board changes on record since 2004: 27 appointments and 17 cessations. The latest: Anilkumar Arvindlal Amin was appointed as Director on 04 Jun 2025.

AGM
Akums Drugs And Pharmaceuticals Limited last Annual general meeting of members was held on 10 Jul 2026 as per latest MCA records.
Charges
A charge with Sbicap Trustee Company Limited of Rs. 85.00 Cr registered on 08 Feb 2023 with Charge ID 100679965 was modified on 02 Jul 2026.
Filing
Akums Drugs And Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Delhi Ii.
Charges
A charge registered on 03 Feb 2020 via Charge ID 100322967 with Others was fully satisfied on 29 Jul 2025.
Appointed
Anilkumar Arvindlal Amin was appointed as Director.
Ceased
Nand Lal Kalra ceased to be Director.
Ceased
Amit Varma ceased to be Director.
Ceased
Basant Kumar Singh ceased to be Whole-Time Director.
Appointed
Sanjay Sinha was appointed as Whole-Time Director.
Appointed
Satwinder Singh was appointed as Director.
Appointed
Sunil Kumar Thakur was appointed as Nominee Director.
Charges
A charge registered on 27 Apr 2010 via Charge ID 10217825 with Standard Chartered Bank was fully satisfied on 14 Aug 2023.

78 earlier events are in the company report.

News

AKUMS: Q2 REVENUE 13.42B RUPEES VS 10.16B (YOY)
02 Nov 2026 · Exchange Update
AKUMS: Q2 CONS NET PROFIT 1.13B RUPEES VS 408M (YOY)
02 Nov 2026 · Exchange Update
AKUMS: Q2 EBITDA 1.95M RUPEES VS 934.8M (YOY); Q2 EBITDA MARGIN 14.51% VS 9.19% (YOY)
02 Nov 2026 · Exchange Update
Akums Drugs And Pharmaceuticals: To Host Analyst And Investor Meeting On September 22 At 10 AM
16 Sep 2026 · Exchange Update

Frequently asked questions

Akums Drugs and Pharmaceuticals is an active public limited company based in Delhi, India. The company works in chemical products, within the chemicals industry. It was incorporated on 19 April 2004 (22+ years old) and is registered under CIN L24239DL2004PLC125888. Listed on BSE: 544222 and NSE: AKUMS.

Akums Drugs and Pharmaceuticals reported revenue of ₹4,359.02 Cr for FY 2025-26 (up 5.8% YoY) based on consolidated financials.

Akums Drugs and Pharmaceuticals has 8 current directors:

The latest financial statements of Akums Drugs and Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 10 July 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Akums Drugs and Pharmaceuticals is 07AAECA7090B2ZX, registered in Delhi. The company has 9 GST registrations in all, of which 5 are active and 4 are cancelled or inactive. Other active GSTINs include 07AAECA7090B4ZV (Delhi), 05AAECA7090B1Z2 (Uttarakhand), 27AAECA7090B1ZW (Maharashtra).

The CIN (Corporate Identification Number) of Akums Drugs and Pharmaceuticals is L24239DL2004PLC125888. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Akums Drugs and Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 544222) and NSE (symbol: AKUMS).

Akums Drugs and Pharmaceuticals has 206 court cases on record: 138 filed by the company and 68 filed against it. 51 are pending. Most are in the high courts.

Akums Drugs and Pharmaceuticals was incorporated on 19 April 2004, making it 22+ years old. It is registered with the Registrar of Companies, Delhi.

Akums Drugs and Pharmaceuticals has 13 deals on record (9 secondary share transfers, 2 market trades, 1 ipo), with disclosed funding of ₹320 Cr; the latest was in December 2025.

The peers of Akums Drugs and Pharmaceuticals by revenue are Strides Pharma Science Limited, Apl Healthcare Limited, J B Chemicals and Pharmaceuticals Limited, Glaxosmithkline Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).

Anilkumar Arvindlal Amin was appointed as Director on 04 Jun 2025. Nand Lal Kalra ceased to be Director on 05 Feb 2025. Amit Varma ceased to be Director on 17 Jan 2024. Akums Drugs and Pharmaceuticals has 44 board changes on record in total.